Key Highlights

● Tenon reported second-quarter 2026 Revenue up roughly 127% to about $1.3 million.

● The company's losses deepened as it invested in commercialization.

● Tenon's Catamaran SI joint fusion system received FDA clearance.

● The company has advanced a next-generation version, the Catamaran SE, with a full market launch.

Tenon Medical, Inc. (NASDAQ:TNON) is a small medical-device company growing sales rapidly for its sacroiliac (SI) joint fusion system. The company's Catamaran technology addresses a niche in spine and pelvic surgery, and its strong revenue growth contrasts with the losses that accompany scaling from a small base.

Tenon embodies the classic micro-cap medical-device dilemma: encouraging commercial traction paired with the losses and cash needs that come with scaling.

Fast Growth, Deepening Losses

Tenon reported second-quarter 2026 revenue up roughly 127% to about $1.3 million, a striking growth rate, but its losses deepened as it invested in commercialization. The company's Catamaran SI joint fusion system received FDA clearance, and Tenon has advanced a next-generation version, the Catamaran SE, announcing initial clinical cases and a full market launch. SI joint fusion addresses lower-back and pelvic pain stemming from the sacroiliac joint, a market where minimally invasive solutions can gain adoption if they demonstrate clinical and procedural advantages. The rapid revenue growth suggests the technology is gaining traction with surgeons, but the deepening losses and small revenue base underscore how far the company must travel to reach sustainable scale.

Business and Financial Position

Tenon Medical develops and markets the Catamaran system for SI joint fusion, competing in a growing but competitive segment of spine and orthopedic surgery. Its model combines capital-equipment and implant sales with the Recurring Revenue that comes from procedures using its devices. As a micro-cap that operates at a loss, Tenon depends on scaling revenue and managing cash, and rapid growth off a small base, while encouraging, requires continued Investment in sales and marketing. Financing needs and potential dilution are recurring considerations for companies at this stage.

Market Context

Micro-cap medical-device stocks with small revenue and ongoing losses are highly volatile, trading on adoption metrics, product news and financing considerations, and can swing sharply on relatively little news. The bull case rests on the strong revenue growth and the Catamaran SE launch; the bear case focuses on the deepening losses, small scale and dilution risk.

A Small Base With Room to Run

The SI joint fusion market has grown as minimally invasive techniques gained acceptance, and Tenon's Catamaran and next-generation Catamaran SE aim to differentiate on procedure and clinical advantages. Triple-digit revenue growth indicates surgeons are trying the technology, but from a very small base, and the deepening losses show how much investment is still required to build a sales force and drive adoption.

What Investors Should Watch

The key signals are continued revenue growth and adoption of the Catamaran SE, gross-margin trends, and progress toward reducing losses. Investors will be monitoring cash runway and any financing, the pace of surgeon and Facility adoption, and competition in SI joint fusion. Execution on scaling a small commercial operation and the company's funding needs are central considerations. Whether Tenon's growth can outpace its losses depends on converting rapid revenue growth into a path toward sustainable economics.